

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Application Number</b>	10/574,438
				<b>Filing Date</b>	04/03/2006
				<b>First Named Inventor</b>	NADESON, Raymond
				<b>Art Unit</b>	1629
				<b>Examiner Name</b>	Savitha M. RAO
<b>Sheet</b>	1	<b>of</b>	3	<b>Attorney Docket Number</b>	DAVI-007/00US 040722-2006

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
		GARY J. BENNETT et al., "A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man," Pain, 1988, Vol. 33: pgs. 87-107			
		DAVID A. BROWN, et al., "Neural KCNQ (Kv7) channels," British Journal of Pharmacology, 2009, Vol. 156; pgs. 1185-1195			
		HUEI-SHENG VINCENT CHEN et al., "The chemical biology of clinically tolerated NMDA receptor antagonists," Journal of Neurochemistry, 2006, Vol. 97: pgs. 1611-1626			
		WAYNE E. CHILDERS JR et al., "N0Methyl-D-Aspartate Antagonists and Neuropathic Pain: The Search for Relief," J. Med. Chem., 2007, Vol. 50: pgs. 2557-2562			
		ANTON J.M. de CRAEN et al., "Analgesic efficacy and safety of paracetamol-codeine combinations versus paracetamol alone: a systematic review," BMJ, 1996, Vol. 313: pgs. 321-325			
		RAYMOND A. DIONNE, "Additive Analgesic Effects of Oxycodone and Ibuprofen in the Oral Surgery Model," J. Oral Maxillofac Surg., 1999, Vol. 57: pgs. 673-678			
		ROBERT H. DWORKIN et al., "Pharmacologic management of neuropathic pain: Evidence-based recommendations," Pain, 2007, Vol. 132: pgs. 237-251			
		BRADLEY S. GALER et al., "Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale," Neurology, 1997, Vol. 48; pgs. 332-338			
		COLIN S. GOODCHILD et al., "Combination Therapy with Flupirtine and Opioid: Open-Label Case Series in the Treatment of Neuropathic Pain Associated with Cancer," Pain Medicine, 2008, Vol. 9, No. 7: pgs. 939-949			
		VALENTINE K. GRIBKOFF, "The therapeutic potential of neuronal KCNQ channel modulators," Expert Opin. Ther. Targets, 2003, Vol. 7, No. 6: pgs. 737-748			

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

**Complete if Known**

<b>Application Number</b>	10/574,438
<b>Filing Date</b>	04/03/2006
<b>First Named Inventor</b>	NADESON, Raymond
<b>Art Unit</b>	1629
<b>Examiner Name</b>	Savitha M. RAO
<b>Attorney Docket Number</b>	DAVI-007/00US 040722-2006

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>		T <sup>2</sup>
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		GUIDELINE CENTRAL, "Guideline: Pharmacologic management of neuropathic pain: Evidence-based recommendations," accessed on February 9, 2010, 19 pages, URL: <a href="http://www.guidelinecentral.com/CustomContentRetrieve.aspx?ID=1826487&amp;A=Search">http://www.guidelinecentral.com/CustomContentRetrieve.aspx?ID=1826487&amp;A=Search</a>	
		P. HLAVICA et al., "Investigation on the Pharmacokinetics and Biotransformations of the Analgesic Flupirtine in Humans," Arzneimittelforschung, 1985, Vol. 35: pgs. 67-74 English Translation	
		REGINA JAKOB et al., "Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurones," British Journal of Pharmacology, 1997, Vol. 122: pgs. 1333-1338	
		SUN HO KIM et al., "An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat," Pain, 1992, Vol. 50: pgs. 355-363	
		J. KORNHUBER et al., "Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels," J. Neural Transm. 1999, Vol. 106: pgs. 857-867	
		MARIA MARTIRE, et al., "M Channels Containing KCNQ2 Subunits Modulate Norepinephrine, Aspartate, and GABA Release from Hippocampal Nerve Terminals," The Journal of Neuroscience, January 21, 2004, Vol. 24, No. 3: pgs. 592-597	
		F. GILBERT McMAHON, et al., "Clinical experience with flupirtine in the U.S.," Postgraduate Medical Journal, 1987, Vol. 63: pgs. 81-85	
		FRANCESCO MICELI, et al., "Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs," Current Opinion in Pharmacology, 2008, Vol. 8: pgs. 65-74	
		GORDON MUNRO, et al., "Kv7 (KCNQ) Channel Modulators and Neuropathic Pain," J. Med. Chem., 2007, Vol. 50: pgs. 2576-2582	
		KIMBALL NILL, "Glossary of Biotechnology Terms," 3 <sup>rd</sup> Edition, CRC Press, 2002: pg13	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.58. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

3

**Complete if Known**

<b>Application Number</b>	10/574,438
<b>Filing Date</b>	04/03/2006
<b>First Named Inventor</b>	NADESON, Raymond
<b>Art Unit</b>	1629
<b>Examiner Name</b>	Savitha M. RAO
<b>Attorney Docket Number</b>	DAVI-007/00US 040722-2006

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		N. N. OSBORNE et al., "Protection of Rabbit Retina From Ischemic Injury by Flupirtine," Investigative Ophthalmology & Visual Science, February 1996, Vol. 37, No. 2: pgs. 274-280	
		C. G. PARSONS, et al., "Comparative Patch-clamp Studies with Freshly Dissociated Rat Hippocampal and Striatal Neurons on the NMDA Receptor Antagonistic Effects of Amantadine and Memantine," European Journal of Neuroscience, 1996, V. 8; pgs. 446-454	
		GAYLE M. PASSMORE, et al., "KCNQ/M Currents in Sensory Neurons: Significance for Pain Therapy," The Journal of Neuroscience, August 6, 2003, Vol. 23, No. 18; pgs. 7227-7236	
		NAVIL F. SETHNA et al., "Analgesic and Cognitive Effects of Intravenous Ketamine-Alfentanil Combinations Versus Either Drug Alone After Intradermal Capsaicin in Normal Subjects," Anesth Analg, 1998, Vol. 86: pgs. 1250-1256	
		MEGUMI SHIMOYAMA et al., "Gabapentin enhances the antinociceptive effects of spinal morphine in the rat tail-flick test," Pain, 1997, Vol. 72: pgs. 375-382	
		HONG-SHENG WANG, et al., "KCNQ2 and KCNQ3 Potassium Channels Subunits: Molecular Correlates of the M-Channel," Science, 1998, Vol. 282; pgs.1890-1893	
		YONG-JIN WU, et al., "(S)-N-[1-(3-Morpholin-4-ylphenyl)ethyl]-3-phenylacrylamide: An Orally Bioavailable KCNQ2 Opener with Significant Activity in a Cortical Spreading Depression Model of Migraine," J. Med. Chem., 2003, Vol. 46: pgs. 3197-3200	
		HEIKE WULFF, et al., "Voltage-gated Potassium Channels as Therapeutic Drug Targets," Nat Rev Drug Discov., December 8, 2008, Vol. 8, No. 12; pgs. 982-1001	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.58. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

